Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

U.S. Tribal Patent Deal Could Impact Generic Drug Market

Jan Wolfe  |  September 12, 2017

(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

Ibuprofen More Likely to Raise BP than Naproxen or Celecoxib

Anne Harding  |  September 12, 2017

NEW YORK (Reuters Health)—Ibuprofen boosts blood pressure (BP) more than naproxen or celecoxib in patients who take non-steroidal anti-inflammatory drugs (NSAIDs) to treat arthritis, according to a new substudy from the PRECISION trial. “These drugs are different with regard to BP, and ibuprofen is the worst,” Dr. Frank Ruschitzka of University Hospital Zurich in Switzerland,…

Care Fragmentation May Increase Risk of SLE Damage & Disease Severity

Arthritis Care & Research  |  September 5, 2017

Despite the wide spread adoption of electronic health records, many systems are unable to exchange data, creating the potential for fragmented care. New research examined the effect of care fragmentation on patients with SLE in the Chicago HealthLNK Data Repository, finding that care fragmentation plays an independent role in an increased frequency of infection and disease-related morbidity damage. Researchers also found a relationship between care fragmentation, race and public insurance…

CMS Announces 90% Cut to Obamacare’s Advertising Budget

Reuters Staff  |  September 4, 2017

WASHINGTON (Reuters)—The U.S. Centers for Medicare and Medicaid Services (CMS) said on Thursday it plans to spend $10 million on advertising for the upcoming Obamacare open enrollment period that starts in November, a sharp cut from the $100 million spent last year. The agency also said it will cut funding for so-called navigators, who help…

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

Reuters Staff  |  August 29, 2017

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report. Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the…

Flimsy Evidence Behind Many FDA Approvals

Will Boggs, MD  |  August 21, 2017

(Reuters Health)—Many drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) lack clear evidence of safety and effectiveness, and the same is true for most high-risk medical devices, according to two new reports in JAMA, online Aug. 15. The Accelerated Approval pathway makes potentially promising investigational medicines available for use before the…

FDA Approves Duzallo for Hyperuricemia in Patients with Uncontrolled Gout

Reuters Staff  |  August 21, 2017

(Reuters)—Ironwood Pharmaceuticals Inc. said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout. The company’s once-daily drug, Duzallo (lesinurad and allopurinol), was approved to treat hyperuricemia in patients with gout, Ironwood said. Duzallo combines the standard-of-care treatment, allopurinol, with Ironwood’s lesinurad to treat inefficient…

Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

Scott Baltic  |  August 19, 2017

NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report. Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb),…

Lipids, Statin Treatment Linked to Revision Rate After Rotator Cuff Repair

Will Boggs, MD  |  August 19, 2017

NEW YORK (Reuters Health)—Elevated lipid levels are associated with an increased revision-surgery rate after arthroscopic rotator cuff repair, while statin use appears to mitigate that increase, according to a database review. “[Although] it supported our hypothesis, we found it interesting to finally demonstrate a link between hyperlipidemia and rotator cuff-repair failure resulting in revision surgery…

Some Jobs Tied to Higher Risk of RA

Lisa Rapaport  |  August 18, 2017

(Reuters Health)—Workers exposed to airborne toxins may have an elevated risk of developing rheumatoid arthritis (RA), an immune system disorder that causes debilitating swelling and pain in the joints, a Swedish study suggests. Among men, bricklayers, concrete workers and electricians had at least twice the risk of RA they would have in certain other occupations,…

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 97
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences